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Abstract
Alcohol consumption is an established risk factor for breast cancer. Nonetheless, the mechanism by
which alcohol contributes to breast tumor initiation or progression has yet to be definitively
established. Studies using cultured human tumor cell lines have identified signaling molecules that
may contribute to the effects of alcohol, including reactive oxygen species and other ethanol
metabolites, matrix metalloproteases, the ErbB2/Her2/Neu receptor tyrosine kinase, cytoplasmic
protein kinases, adenylate cyclase, E-cadherins, estrogen receptor, and a variety of transcription
factors. Emerging data suggest that the epidermal growth factor receptor (EGFR) tyrosine kinase
may contribute to breast cancer genesis and progression. Here we integrate these findings and propose
three mechanisms by which alcohol contributes to breast cancer. A common feature of these
mechanisms is increased EGFR signaling. Finally, we discuss how these mechanisms suggest
strategies for addressing the risks associated with alcohol consumption.
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Alcohol and other breast cancer risk factors
One in eight American women will be stricken with breast cancer, which is the second leading
cause of cancer-related mortality among American women.1 Approximately 15% of those
breast cancer patients who receive surgery and chemotherapy will experience a recurrence of
the disease. This is a major contributor to the fact that one-third of those who develop breast
cancer will ultimately succumb to the disease.2 Thus, breast cancer remains an important public
health and societal issue and more information is needed concerning the causes of breast cancer
and risk factors associated with the disease.
In 50% of breast cancers the only apparent risk factors are gender and age.1,2 In the other half
of breast cancers the risk factors include genetic factors, environmental factors, age of
menarche and menopause, and reproductive history.2 The latter factors underscore the
contributions of female reproductive hormones to breast cancer risk.2
ErbB family receptor tyrosine kinases and their ligands, members of the epidermal growth
factor (EGF) family of peptide growth factors, also play significant roles in breast cancer
pathogenesis and progression. The ErbB2 receptor tyrosine kinase, also known as HER2/Neu,
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is overexpressed in a significant fraction of breast tumors and this overexpression correlates
with the absence of steroid hormone receptor expression and with poor disease prognosis.3–
5 Constitutive ErbB2 signaling causes mammary malignancies in transgenic mouse model
systems6,7 and causes malignant growth transformation in cell culture models of breast cancer.
8,9 Moreover, agents that target ErbB2 are moderately effective at controlling ErbB2-positive
breast tumors when these agents are administered as part of a combination chemotherapy
regimen.10
Although EGF receptor (EGFR) overexpression is observed in breast tumors,11 the potential
roles that EGFR signaling may have in the development or progression of breast cancer are
not as well-characterized as those played by ErbB2.12 Nonetheless, EGFR expression and
signaling have been postulated to play roles in the genesis, maintenance, or progression of
breast tumors. EGFR appears to be of particular relevance to breast cancer stem cells, triple
negative tumors, and basal-type tumors. For example, breast cancer stem cells that exhibit
elevated EGFR signaling display resistance to endocrine therapy13 as well as uncontrolled self-
renewal and unlimited proliferation.14 Approximately 60% of basal-type and triple-negative
tumors display elevated EGFR expression. Basal-type and triple-negative breast tumors are
typically devoid of estrogen receptor (ER) and HER2 (ErbB2/Neu) expression and are therefore
resistant to existing targeted therapies. Thus, EGFR is an attractive target in these types of
breast tumors.15 Indeed, a combination of carboplatin and the EGFR tyrosine kinase inhibitor
cetuximab (Erbitux) synergistically inhibits proliferation of basal-type breast cancer cell lines.
16
Endogenous ligands for ErbB receptors also appear to play important roles in human breast
cancers. For example, the EGFR ligand amphiregulin stimulates breast tumor cell motility17
and is sufficient and necessary for tumor cell expression of parathyroid hormone-related protein
(PTHrP), an important contributor to tumor cell invasion and colonization of bone.18,19
Reduced expression of matrix metalloproteases (MMPs) in SCP20 human breast tumor cells
is associated with decreased osteoclastic stimulation by these cells and reduced amphiregulin
release by these cells. These data suggest that amphiregulin/EGFR signaling is coupled to bone
colonization of breast tumor cells and can be regulated by matrix metallproteases. Indeed, the
EGFR antagonistic antibody cetuximab or the EGFR tyrosine kinase inhibitor gefinitib inhibits
bone metastasis by SCP20 cells in mouse xenograft assays.20 Moreover, the fact that EGFR
ligands can stimulate ErbB2 signaling through heterodimerization with EGFR21 suggests that
EGFR and its ligands may play a significant role in at least some ErbB2-dependent breast
tumors. Indeed, pharmacological agents that target EGFR or its ligands continue to be
investigated as potential breast cancer therapeutics.22–24
Several environmental factors appear to contribute to breast cancer risk, including ionizing
radiation, pesticides, and diet.2 A number of studies have identified an association between
moderate alcohol consumption and increased breast cancer risk.25–29 For example, average
consumption of 14 or more drinks per week in a five-year period prior to breast cancer diagnosis
increased breast cancer risk by 82%.30
Alcohol may exert its effects via several mechanisms
There appear to be multiple mechanisms by which alcohol may contribute to breast
malignancies or may modulate the behavior of mammary epithelial and tumor cells in vivo and
in vitro. Alcohol is metabolized in a variety of tissues, including the breast. Alcohol
dehydrogenase converts ethanol to acetaldehyde, which can form adducts of DNA and can
cause DNA cross-links and G:A transitions at A:T base pairs. Indeed, acetaldehyde displays
weak mutagenic and carcinogenic activity.29,31 Xanthine oxidoreductase and aldehyde oxidase
are found in breast tissue and metabolize acetaldehyde to reactive oxygen species (ROS),
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including the superoxide anion free radical (O2•−), the neutral hydroxide free radical (OH•),
and hydrogen peroxide (H2O2). These ROS can contribute to breast malignancies via a variety
of mechanisms, including DNA mutation, base deletion, and single and double strand breaks.
29,31
Additional mechanisms may underlie the contributions of ethanol to breast malignancies.
Alcohol at a concentration as low as 0.06% stimulates the expression of estrogen receptor alpha
(ERα) and the estradiol biosynthesis enzyme aromatase in human breast cancer cell lines.32,
33 In fact, moderate alcohol consumption of 0.7 g/kg is associated with an elevated estrogen
concentration in the plasma of postmenopausal women.34,35 In cell line model systems alcohol
concentrations of 0.06% to 0.6% stimulate transcription from the estrogen response
element36 and increased transcription of the progesterone receptor and pS2, two genes whose
transcription is regulated by ER.37 Alcohol stimulation of ER-dependent gene expression may
account for the observation that alcohol stimulates proliferation in ER-positive MCF7 human
breast tumor cells but has no effect on the proliferation of ER-negative MDA-MB-231 and
BT-20 human breast tumor cell lines.33 However, it is has yet to be demonstrated that changes
in ER-dependent gene expression underlie the effects of alcohol on the malignant phenotypes
of breast tumor cells.
Alcohol induces other intracellular signaling events. Increased expression of the c-Fos
transcription factor is observed in NIH 3T3 cells one hour after treatment with 0.2% alcohol.
This increase persists up to 96 hours after treatment with alcohol.38 Likewise, alcohol
concentrations of 1.3% to 5.1% stimulate phosphorylation of the c-Jun NH2-terminal protein
kinase (JNK), the p38 mitogen-activated protein kinase (p38 MAPK), and phosphatidylinositol
3-kinase (PI3K).39,40 Finally, alcohol concentrations as low as 0.12% inhibit expression of the
adhesion molecule E-cadherin and cause an increase in cell migration.41 E-cadherin is a tumor
suppressor and loss of E-cadherin expression contributes to tumor progression by enhancing
metastatic phenotypes.42
Metalloproteases are zinc-dependent endopeptidases. These enzymes are expressed in an
inactive, secreted, or transmembrane precursor form. The interaction of a zinc ion with three
histidine residues and a cysteine residue (cysteine “switch” residue) hold the metalloprotease
in an inactive conformation. Metalloproteases can be activated through cleavage by
convertases such as furin. ROS can activate metalloproteases by oxidizing the cysteine switch
residue, thereby disrupting its interaction with the zinc ion and allowing the enzyme to adopt
an active conformation.43 Active tumor cell metalloproteases degrade components of the
extracellular matrix, such as gelatin and collagens, thereby contributing to tumor cell
invasiveness and metastasis.44,45 In breast cancer cell lines, alcohol concentrations of 1.3% to
5.1% stimulate the expression and secretion of MMPs 2 and 9.39,46,47 Thus, it is not surprising
that alcohol stimulates invasiveness and anchorage-independent proliferation of MCF7 human
mammary tumor cells.32,41 Moreover, small interfering RNAs (siRNAs) specific for MMP2
or small molecule inhibitors of MMP2 reduce the effect of alcohol on anchorage-independent
proliferation.39
Alcohol appears to stimulate metalloprotease activity via a variety of mechanisms. As
discussed earlier, alcohol is metabolized to ROS,48–50 which then can stimulate
metalloprotease activity.51,52 Thus, it is reasonable to postulate that ROS and their regulation
of metalloproteases mediate at least some of the effects of alcohol on the malignant phenotypes
of breast tumor cells. Indeed, ROS scavengers inhibit alcohol stimulation of metalloprotease
activity and alcohol stimulation of tumor cell invasiveness.39
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Alcohol may stimulate tumor cell aggressiveness through increased EGFR
signaling
Experiments in fruit flies indicate that increased signaling of EGFR through Erk, but not
through p38 or JNK, inhibits the sedative effects of alcohol. Moreover, the sedative effects of
alcohol exposure in fruit flies or alcohol consumption by rats appear more rapidly in animals
treated with the EGFR tyrosine kinase inhibitor erlotinib. These data suggest that EGFR
signaling modulates pathways that couple alcohol to its behavioral effects.53 In subsequent
paragraphs we will discuss numerous other observations that support the hypothesis that EGFR
signaling couples alcohol to biological responses, particularly malignant phenotypes of breast
tumor cells.
Most EGF family peptide growth factors are expressed as transmembrane precursors. Active
metalloproteases cleave these precursors, releasing a mature, soluble form of the growth factor
that binds ErbB receptors and stimulates their signaling.43 Agonists for numerous serpentine
G protein-coupled receptors (GPCRs) regulate the cleavage of EGF family precursors by
metalloproteases, thereby enabling GPCR agonists to stimulate ErbB receptor signaling and
coupling to biological responses.51,54 For example, MMP9 and MMP2 are required for agonists
of the Gq-coupled gonadotropin receptor to stimulate EGFR tyrosine phosphorylation and
induction of the downstream transcription factors c-Fos and c-Jun.51,55 Similarly, the GPCR
agonists lysophosphatidic acid (LPA) and carbachol stimulate cleavage and maturation of the
precursor form of amphiregulin (AR) by the metalloprotease ADAM17, resulting in enhanced
cell migration and increased DNA synthesis.17,56 Phenylpherine stimulates cleavage of the
precursor form of heparin-binding EGF-like growth factor (HB-EGF) by MMP7, leading to
arterial vasoconstriction.51,57 GPCR transactivation of EGFR signaling also stimulates the
activity of the c-Jun NH2-terminal protein kinase (JNK), the p38 mitogen-activated protein
kinase (p38 MAPK), and phosphatidylinositol 3-kinase (PI3K).51 It should be reiterated that
the activity of JNK, MAPK, PI3K, c-fos, and c-jun increases upon treatment with alcohol,39,
40,51,55 suggesting that alcohol may activate signaling pathways that are also activated by
Gαq-coupled or Gαi-coupled GPCRs and that may include EGFR and its effectors. Indeed,
angiotensin (AT) stimulation of the Gαq-coupled AT receptor I leads to ROS production, which
in turn stimulates ADAM17-dependent cleavage of HB-EGF.51 Recall that alcohol is
metabolized to ROS. Consequently, we postulate that alcohol metabolism to ROS and
subsequent stimulation of metalloprotease activity by ROS could result in increased processing
of EGF family precursor proteins and increased EGFR signaling (Figure 1). Indeed,
preliminary data from our laboratory indicates that 1% alcohol stimulates MCF7 human breast
tumor cells to release AR into the culture medium.
Alcohol concentrations of 0.1% to 0.3% stimulate the transcription of genes whose promoter
contains a cyclic AMP (cAMP) response element (CRE).37 Indeed, alcohol stimulates the
activity of some adenylate cyclases (ACs), apparently by stabilizing the enzyme in the active
conformation.58,59 This leads to increased cAMP production, protein kinase A (PKA) activity,
phosphorylation of the CRE binding protein (CREB) by PKA, and increased transactivation
of CRE promoters by phosphorylated CREB. Because the amphiregulin promoter contains a
CRE,17 it is reasonable to speculate that alcohol may stimulate EGFR signaling through a
cAMP-dependent increase in amphiregulin transcription (Figure 2). Indeed, vasoactive
intestinal peptide (VIP), which stimulates cAMP production through a Gαs-coupled GPCR,
also stimulates EGFR tyrosine phosphorylation in colonic epithelial cells.60
As discussed earlier, alcohol stimulates transcriptional activation by the estrogen receptor. The
details of the mechanism by which this occurs remain unclear. Nonetheless, alcohol stimulates
ERα and aromatase expression32,33 and estrogen stimulates ER-dependent TGFα and
amphiregulin gene expression.61–63 Thus, alcohol may stimulate biological responses in breast
Mill et al. Page 4













tumor cells through ERα stimulation of EGFR ligand expression and EGFR signaling. This
hypothesis is consistent with our preliminary observation that 1% alcohol stimulates MCF7
human breast tumor cells to express AR and release it into the culture medium.
Estrogen can also rapidly modulate cellular signaling pathways in the cytosol and at the
membrane in the absence of any direct effect of ER on gene expression.64,65 Some of these
nongenomic responses are mediated by a GPCR that stimulates Gαi, resulting in activation of
matrix metalloproteases and cleavage of the proform of an EGF family growth factor (Figure
1).64 Other effects appear to be mediated by Gαs, resulting in elevated PKA activity and cAMP
accumulation (Figure 2).65 As discussed earlier, this could result in elevated amphiregulin
expression via the CRE present in the amphiregulin promoter.
EGFR signaling can modulate ER-dependent signaling.64 EGFR can couple to the PI3K/Akt
pathway, leading to IKK phosphorylation of the estrogen receptor and modulation of ER-
dependent gene expression.66 EGFR signaling can also couple to increased Erk and Jnk
activity, resulting in the phosphorylation of various transcription factors, including CREB-
binding protein (CBP). Phosphorylated CBP can dimerize with estrogen receptor, leading to
ER-dependent gene transcription.64 Thus, EGFR signaling may lie upstream or downstream
of ER in alcohol-induced signaling pathways.
As discussed earlier, alcohol inhibits expression of the cell adhesion tumor suppressor protein
E-cadherin, leading to an increase in cell migration.41 EGFR signaling is coupled to
inactivation of the E-cadherin/β-catenin complex in tumor cell lines, thereby contributing to
metastatic phenotypes.67–70 In fact, treatment of lung cancer cell lines with EGFR monoclonal
antibodies results in increased E-cadherin expression.71 Thus, increased EGFR signaling may
be responsible for the decrease in E-cadherin expression observed following alcohol treatment.
A hallmark of EGFR signaling is phosphorylation of EGFR on cytoplasmic tyrosine residues.
This phosphorylation creates docking sites for effector binding and coupling. Thus,
dephosphorylation of these tyrosine residues by phosphatases negatively regulates EGFR
coupling to effector proteins and biological responses.72–74 There is emerging evidence
suggesting that alcohol enhances EGFR signaling by inactivating phosphatases that catalyze
EGFR dephosphorylation (Figure 3). Recall that alcohol is metabolized to ROS in breast tissue.
These ROS can oxidize a conserved, essential cysteine residue in the catalytic domain of
phosphatases, thereby disrupting the catalytic activity of the phosphatases.49,75,76 Therefore,
it is plausible to postulate that alcohol may stimulate increased EGFR signaling through ROS-
mediated inactivation of the phosphatases that dephosphorylate EGFR tyrosine residues.
Indeed, it has been suggested that ultraviolet light and other cellular stresses that contribute to
the production of intracellular ROS cause increased EGFR signaling via this mechanism.77
Agonist binding to EGFR can cause EGFR heterodimerization with ErbB2, leading to
phosphorylation of both receptor molecules and coupling of both receptors to downstream
signaling events. Because ErbB2 does not possess soluble agonists, this is an important
mechanism by which ErbB2 signaling can be regulated.78 This heterodimerization of ErbB2
with EGFR may contribute to the effect alcohol has on breast tumor cell behavior. Indeed, this
model is supported by the observation that ErbB2 overexpression potentiates the effect of
alcohol on invasiveness and other malignant phenotypes of breast cancer cell lines.39–41,79
ErbB2 overexpression is also associated with increased transcription of MMP2 and
MMP939,47 and siRNA knockdown of endogenous ErbB2 overexpression is associated with
reduced MMP activity.39
Finally, amphiregulin induces EGFR coupling to increased expression of MMP2 and MMP9
in breast tumor cell lines; antisense knockdown of amphiregulin expression in the NS2T2A1
breast tumor cell line results in decreased expression of MMP2.17 Thus, alcohol stimulation
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of MMP expression and activity as described in this review may establish a feed forward
mechanism that features increased amphiregulin stimulation of EGFR/ErbB2 signaling. This
signaling is then coupled to increased expression of MMP2 and MMP9, which contributes to
further increases in signaling by the amphiregulin/EGFR/ErbB2 axis and deregulated cellular
proliferation, motility, and invasiveness.
Here we postulate three mechanisms by which alcohol may contribute to breast tumor genesis,
progression, or aggressiveness. Additional experimentation is necessary to decipher which, if
any, of these mechanisms are relevant. These experiments should proceed with an
understanding that these mechanisms are not likely to be mutually exclusive. Indeed, at
different stages during breast cancer progression distinct mechanisms may be relevant.
The mechanisms discussed here may have important implications in understanding breast
cancer progression and potential therapies. Given that alcohol may stimulate estrogen receptor,
EGFR, and ErbB2/Her2/Neu signaling, even moderate alcohol consumption may affect the
outcome of breast cancer patients whose tumors express these proteins. Moreover, given the
central role that ROS and estrogen may have in mediating the effects of alcohol on breast tumor
genesis, progression, or aggressiveness, antioxidants and antiestrogens may hold value in
blocking the negative effects of alcohol on breast cancer.
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Alcohol may mimic G-protein coupled receptor transactivation of EGFR. Signaling by Gq/i-
coupled receptors contributes to the production of reactive oxygen species (ROS). These ROS
oxidize a cysteine residue in the catalytic cleft of the ADAM, thereby disrupting the interaction
between the zinc ion and the ADAM protein. Disruption of this interaction causes the ADAM
protein to adopt an active conformation. Active ADAM proteins can then cleave the precursor
form of EGF family growth factors. The cleaved factors bind EGFR and stimulate its signaling
activity. Because alcohol causes intracellular accumulation of ROS, it is predicted to stimulate
EGFR signaling.
Abbreviations: AT II, angiotensin II; LPA, lysophosphatidic acid; EtOH, ethanol; GPCR, G-
protein coupled receptor; ROS, reactive oxygen species; HB-EGF, heparin-binding, EGF-like
growth factor; AR, amphiregulin; EGF, epidermal growth factor; BTC, betacellulin;
TGFalpha, transforming growth factor alpha; EGFR, EGF receptor.
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Alcohol may mimic G-protein coupled receptor stimulated transcription of amphiregulin, an
EGF family growth factor. Signaling by Gs-coupled receptors stimulates adenylate cyclase
(AC) production of cAMP. This increases phosphorylation of the transcription factor CREB
(cAMP response element binding protein) by protein kinase A (PKA). CREB promotes the
transcription of the EGF family growth factor amphiregulin (AR), resulting in increasing EGFR
signaling. Alcohol stabilizes AC in the active conformation, resulting in increased PKA
activity. Thus, alcohol is predicted to stimulate AR transcription and EGFR signaling.
Abbreviations: VIP, vasoactive intestinal peptide; GPCR, G-protein coupled receptor; EtOH,
ethanol; AC, adenylate cyclase; PKA, protein kinase A; CRE, cyclic AMP response element;
CREB, CRE-binding protein; pCREB, phosphorylated CREB; AR, amphiregulin; EGFR, EGF
receptor.
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Alcohol may inhibit phosphatases that negatively regulate EGFR. The protein tyrosine
phosphatase PTP-1B inhibits EGFR signaling by catalyzing the dephosphorylation of EGFR
tyrosine residues. ROS can oxidize a catalytic cysteine residue of protein phosphatases, thereby
inactivating them and leading to increased EGFR signaling. Because alcohol causes
intracellular accumulation of ROS, it is predicted to stimulate EGFR signaling.
Abbreviations: EtOH, ethanol; ROS, reactive oxygen species; PTP-1B, protein tyrosine
phosphatase 1B; EGFR, EGF receptor.
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